TFPI

TFPI

TFPI Overview

Molecule Name
Tissue factor pathway inhibitor
Synonyms
TFPI,LACI,TFPI1,EPI,TFI
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs2
Highest Development StageApproved
Target Synonym
TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Background
Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
KN-057KN-057; KN057Phase 3 ClinicalSuzhou Alphamab Co Ltd
Hemophilia A; Hemophilia B
Details
MG-1113MG-1113; MG-1113APhase 1 ClinicalGC Biopharma Corp
Hemophilia A
Details
AP-017AP017; AP-017Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Hemophilia A; Hemophilia B
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
ConcizumabAnti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021ApprovedNovo Nordisk A/SAlhemoCanadaHemophilia BNovo Nordisk Canada Inc2023-04-17
Hemophilia A; Hemophilia B; Hemorrhage
Details
MarstacimabPF-6741086; PF-06741086ApprovedPfizer IncHYMPAVZI, 友瑞宁United StatesHemophilia A; Hemophilia BPfizer Inc2024-10-11
Hemophilia A; Hemophilia B; Hemorrhage
Details